오토인젝터 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Autoinjectors Market was valued at USD 115 billion in 2025 and is estimated to grow at a CAGR of 14.4% to reach USD 430.8 billion by 2035.

Market growth is being fueled by the rising adoption of targeted therapies, expanding availability of generic autoinjectors, and increasing demand for convenient self-administration devices. Autoinjectors are advanced drug delivery systems designed to automatically administer a predetermined dose of medication through a needle with minimal user effort. These devices are widely used for the self-administration of therapies for chronic conditions, including diabetes, rheumatoid arthritis, allergies, and other long-term diseases. Their user-friendly design, typically supported by a spring-powered injection mechanism, makes them particularly suitable for patients requiring regular injections. The increasing prevalence of severe allergic reactions is further accelerating demand for emergency drug delivery devices that enable rapid self-administration during critical situations. In addition, broader access to cost-effective generic autoinjectors is improving treatment affordability and expanding patient access across global healthcare markets. Continuous product innovation, improved patient convenience, and growing preference for home-based treatment continue to reinforce the long-term growth outlook for the autoinjectors market.

The disposable autoinjectors segment held 66.5% share in 2025, supported by the convenience, safety, and ease of use offered by single-use devices across a broad range of therapeutic applications. Disposable autoinjectors are supplied prefilled and intended for one-time administration, eliminating the need for cartridge replacement while minimizing contamination risks and dosing inaccuracies. Their high reliability and simplified operation have encouraged widespread adoption for the treatment of chronic diseases that require consistent and accurate medication delivery over extended periods.

The homecare settings segment captured a 64.2% share in 2025 driven by the increasing shift toward self-administration and patient-centered healthcare models. Patients continue to favor home-based treatment because it offers greater convenience, lowers healthcare expenses, and supports independent management of chronic conditions. Autoinjectors provide safe, precise, and user-friendly drug administration without requiring direct medical supervision, making them an ideal solution for long-term injectable therapies while improving treatment adherence and patient satisfaction.

North America Autoinjectors Market accounted for 46.9% share in 2025. Regional expansion is supported by the growing prevalence of chronic diseases that require routine injectable therapies, increasing awareness of self-administered treatment options, and the widespread adoption of advanced drug delivery technologies. Continued demand for convenient, reliable, and patient-friendly injection devices, along with a well-established healthcare infrastructure, is expected to sustain market growth across the region.

Key players operating in the global autoinjectors market include Novo Nordisk, AbbVie, Gerresheimer, Eli Lilly and Company, Becton, Dickinson and Company, Johnson & Johnson, SHL Medical, Halozyme, Owen Mumford, Teva Pharmaceuticals, GlaxoSmithKline, Mylan, Antares Pharma, West Pharmaceutical Services, Ypsomed, and Amgen. Companies operating in the autoinjectors market are strengthening their competitive position by investing in advanced drug delivery technologies, expanding product portfolios, and enhancing patient-centric device designs. Manufacturers are focusing on developing user-friendly, ergonomic, and highly reliable autoinjectors that improve treatment adherence and overall patient experience. Strategic partnerships with pharmaceutical companies, healthcare providers, and distribution networks are helping expand commercial reach and support combination product development. Businesses are also increasing investments in research and development to improve injection mechanisms, safety features, and device compatibility with biologics and specialty drugs. In addition, companies continue to pursue regulatory approvals, geographic expansion, manufacturing capacity enhancements, and the introduction of cost-effective generic autoinjectors to broaden market access and reinforce long-term market leadership.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Type trends
  • 2.2.3 Route of administration trends
  • 2.2.4 Therapy trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing demand for targeted therapies
    • 3.2.1.2 Availability of generic autoinjectors globally
    • 3.2.1.3 Increasing incidence of diabetes and anaphylaxis
    • 3.2.1.4 Rising patient preference towards self-administration of medication
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Availability of alternative treatment options
    • 3.2.2.2 High pricing of the autoinjectors
    • 3.2.2.3 Limited autoinjector manufacturing capacity
  • 3.2.3 Opportunities
    • 3.2.3.1 Adoption of smart and connected autoinjectors
    • 3.2.3.2 Expansion of biosimilar and biologic drug launches
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Pricing trend analysis (Driven by Primary Research)
• 3.6 Technology and innovation landscape (Driven by Primary Research)
  • 3.6.1 Current technological trends
  • 3.6.2 Emerging technologies
• 3.7 Future market trends (Driven by Primary Research)
• 3.8 Impact of AI & Generative AI on the Market (Driven by Primary Research)
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis (Driven by Primary Research)
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
  • 4.3.5 LAMEA
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Disposable
• 5.3 Reusable

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Subcutaneous
• 6.3 Intramuscular

Chapter 7 Market Estimates and Forecast, By Therapy, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Rheumatoid arthritis
• 7.3 Multiple sclerosis
• 7.4 Anaphylaxis
• 7.5 Diabetes
• 7.6 Other therapies

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital and clinics
• 8.3 Homecare settings
• 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AbbVie
• 10.2 Amgen
• 10.3 Antares Pharma
• 10.4 Becton, Dickinson and Company
• 10.5 Eli Lilly
• 10.6 Gerresheimer
• 10.7 GlaxoSmithKline
• 10.8 Halozyme
• 10.9 Johnson & Johnson
• 10.10 Mylan
• 10.11 Novo Nordisk
• 10.12 Owen Mumford
• 10.13 SHL Medical
• 10.14 Teva Pharmaceuticals
• 10.15 West Pharmaceutical Services
• 10.16 Ypsomed